Technical Analysis for MRUS - Merus N.V.

Grade Last Price % Change Price Change
grade F 13.4 -1.90% -0.26
MRUS closed down 1.9 percent on Wednesday, May 22, 2019, on 10 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MRUS trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Pocket Pivot Bullish Swing Setup -1.90%
Volume Surge Other -1.90%
Fell Below 50 DMA Bearish -1.18%
Crossed Above 50 DMA Bullish -9.40%
180 Bullish Setup Bullish Swing Setup -9.40%
Outside Day Range Expansion -9.40%
50 DMA Resistance Bearish -3.25%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.25%

Older signals for MRUS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Medicine Health Immunology Solid Tumors Antibodies Monoclonal Antibodies Cancer Immunotherapy Acute Myeloid Leukemia Myelodysplastic Syndrome Monoclonal Antibody Therapy Europe Ovarian Cancers
Is MRUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.74
52 Week Low 11.0
Average Volume 28,934
200-Day Moving Average 15.0227
50-Day Moving Average 14.1777
20-Day Moving Average 14.6142
10-Day Moving Average 13.935
Average True Range 1.0659
ADX 19.13
+DI 14.0499
-DI 21.2602
Chandelier Exit (Long, 3 ATRs ) 14.4023
Chandelier Exit (Short, 3 ATRs ) 15.6977
Upper Bollinger Band 16.541
Lower Bollinger Band 12.6874
Percent B (%b) 0.18
BandWidth 26.368874
MACD Line -0.2461
MACD Signal Line -0.0809
MACD Histogram -0.1652
Fundamentals Value
Market Cap 259.91 Million
Num Shares 19.4 Million
EPS -5.48
Price-to-Earnings (P/E) Ratio -2.45
Price-to-Sales 36.17
Price-to-Book 3.52
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.00
Resistance 3 (R3) 14.02 13.83 13.90
Resistance 2 (R2) 13.83 13.68 13.83 13.87
Resistance 1 (R1) 13.62 13.59 13.53 13.60 13.83
Pivot Point 13.43 13.43 13.39 13.43 13.43
Support 1 (S1) 13.22 13.28 13.13 13.20 12.97
Support 2 (S2) 13.03 13.19 13.03 12.93
Support 3 (S3) 12.82 13.03 12.90
Support 4 (S4) 12.80